Detalhe da pesquisa
1.
Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers.
Proc Natl Acad Sci U S A
; 111(8): 3128-33, 2014 Feb 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-24520176
2.
Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.
Oncotarget
; 11(14): 1289, 2020 Apr 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32292577
3.
The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.
Oncotarget
; 9(81): 35226-35240, 2018 Oct 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-30443290